The field of vaccines and immunization has been transformed
globally over the last 40 years; however, the system is now in
crisis, with vaccine shortages and R&D efforts considered
costly and lengthy.
GAVI, the Global Vaccine Alliance, has proven to be a strong
catalyst for vaccination in developing countries and continues to
make an extremely important contribution to preventative medicine,
and to social and economic development. But, overall, vaccination
coverage levels remain stagnant and 20% of the worldwide birth
cohort does not receive a single vaccine, despite some of the
vaccines costing only a few cents per dose.
The Ebola epidemic and the lack of new antibiotics, highlight
the problem as R&D manufacturers invest in treatments for more
lucrative diseases, rather than develop vaccines to address
emerging or neglected diseases.
In order to remain healthy, the vaccination ecosystem needs to
provide returns on investment for donors (such as: Bill &
Melinda Gates Foundation, USAID, NORAD and others) but also
- Multiple suppliers are needed to avoid sole supplier situations
and to help secure supply.
- The development of vaccines for diseases that predominantly or
exclusively burden poorer countries and funding for R&D
activities must be secured.
- The support of existing vaccination programs also needs to
remain in focus. Supply shortages have been identified by SAGE
(Strategic Advisory Group of Experts on Immunization) as a key
hurdle in achieving vaccination goals. The current vaccine market
appears to be not attractive enough for new market entrants to fill
- Ongoing support is needed to sustain the vaccination policy
efforts when a country no longer qualifies for GAVI funding -
countries with a gross national income per capita above the
eligibility threshold are no longer be available for funding.
In a world in which thousands of children continue to die from
preventable infectious diseases every year, failure is not an
Click on the slide on the right hand side to expand it, or
download the white paper below.
Source : Kantar Health